BOSTONMassachusetts state officials say they found unclean conditions including visible black specks of fungus in steroids made by a pharmacy linked to a deadly outbreak of meningitis.
Gov. Deval Patrick said Tuesday the state has moved to revoke the license of the New England Compounding Center and three pharmacists. The state also said it is launching a criminal investigation into the company that is identified as the source of a 17-state meningitis outbreak.
State officials say a preliminary investigation found drugs were sent out before tests results on their sterility could be returned. They also said the company operated as a drug manufacturer by producing drugs for broader use, rather than filling out specific prescriptions for specific doctors, which is all its license allowed.
CBS Evening News medical correspondent Dr. Jon LaPook reports a lack of basic laboratory standards at the specialty pharmacy as revealed by the investigation. He notes the lab had dirty floor mats, a leaky boiler, did not adequately sterilize medications, and did not properly test its laboratory equipment.
and 23 have died. All had received contaminated steroid injections, mostly for back pain. Four of the cases may be fungal joint infections from patients who received shots in the knees, hips, and shoulders, the Centers for Disease Control and Prevention said Tuesday.
The company says it's cooperating with investigators.
Federal health officials matched the shots produced by the company to the outbreak after finding a deadly fungus in more thanthere but have not said how the shots were contaminated.
The fungus, called Exserohilum rostratum, is common in the environment but has never before been identified as a cause of meningitis, according to the CDC.
The contaminated lots of methylprednisolone acetate were sent to 76 facilities in 23 states. Federal officials estimated up to 14,000 patients may have received the injections -- 97 percent of those patients have been contacted, the CDC said.}
A congressional committee on Monday sought a decade's worth of records from the company as new state documents detailed problems an outside firm hired to do an assessment found there in 2006.
Theobtained by CBS News say investigators in 2006 found inadequate contamination control and no written standard operating procedures for using equipment, among other problems, at the New England Compounding Center. The problems were corrected that year, and a state inspection in May 2011 as the company prepared to update its facilities found no such issues.
In a letter sent Monday to a lawyer for NECC, the House Committee on Energy and Commerce seeks nearly 10 years of documents about safety and quality issues at the company. It indicates that as far back as 2002 and 2003 officials from the Food and Drug Administration and the state conducted joint probes of the company after receiving a report about a steroid shot. Those probes preceded a 2004 joint investigation of the center by FDA and the Massachusetts Board of Registration in Pharmacy.
In January 2006, based on several complaints, the company signed with state regulators a consent agreement in which it agreed to a full inspection of its drug compounding practices by investigators.
The company's encounters with regulators have been reported since the outbreak began, but state pharmacy board documents released Monday offer a new level of detail. They show the inspection by Illinois-based Pharmaceutical Systems Inc. found "significant gaps" in procedures and a lack of required documentation at the NECC facility in Framingham, just west of Boston.
NECC spokesman Andrew Paven said he hadn't seen the committee's letter but the company continues to cooperate with the ongoing investigation.
"NECC worked cooperatively with the Massachusetts Board of Registration in Pharmacy to resolve to the Board's satisfaction any issues brought to the company's attention," he said by email.
NECC attorney Paul Cirel told CBS News in a statement Tuesday evening, "It has always been the company's practice to provide the Board with full and complete access to its facility and its records. As is standard practice in the health care industry, the Board had numerous opportunities, including as recently as last summer, to make first-hand observations of the NECC's facilities and operations."
"Based on that history, it is hard to imagine that the Board has not been fully apprised of both the manner and scale of the company's operations," Cirel said. "NECC's transparency in dealing with the Board since inception in 1998 demonstrates its good faith intention to operate in compliance with the requirements of its license. Furthermore, the company's intention and best efforts at compliance are equally applicable in every other state in which it has been licensed."